Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer
- 30 July 2018
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 78 (15), 4282-4291
- https://doi.org/10.1158/0008-5472.can-17-3821
Abstract
Immunotherapy in pancreatic ductal adenocarcinoma (PDA) remains a difficult clinical problem despite success in other disease types with immune checkpoint blockade (ICB) and chimeric antigen receptor T cell therapy. Mechanisms driving immunosuppression and poor T cell infiltration in PDA are incompletely understood. Here we use genetically engineered mouse models of PDA that recapitulate hallmarks of human disease to demonstrate that CD40 pathway activation is required for clinical response to radiotherapy (RT) and ICB with αCTLA-4 and αPD-1. The combination of an agonist αCD40 antibody, RT, and dual ICB eradicated irradiated and unirradiated (i.e. abscopal) tumors, generating long-term immunity. Response required T cells and also short-lived myeloid cells and was dependent on the long non-coding RNA myeloid regulator Morrbid. Using unbiased random forest machine learning, we built unique, contextual signatures for each therapeutic component, revealing that (i) RT triggers an early proinflammatory stimulus, ablating existing intratumoral T cells and upregulating MHC class I and CD86 on antigen presenting cells, (ii) αCD40 causes a systemic and intratumoral reorganization of the myeloid compartment, and (iii) ICB increases intratumoral T cell infiltration and improves the CD8 T cell:regulatory T cell ratio. Thus, αCD40 and RT non-redundantly augment anti-tumor immunity in PDA, which is otherwise refractory to ICB, providing a clear rationale for clinical evaluation.Other Versions
Funding Information
- HHS | NIH | National Cancer Institute (NCI) (CA210944)
- HHS | NIH | National Cancer Institute (NCI) (CA169123)
- HHS | NIH | National Cancer Institute (NCI) (CA016520)
- HHS | NIH | National Cancer Institute (NCI) (CA172651)
- HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) (AI128060)
- HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (DK111755)
- HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) (HL136572)
- HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) (HL138739)
- Pew Charitable Trusts
This publication has 43 references indexed in Scilit:
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Random forests for genomic data analysisGenomics, 2012
- Tumor-Derived Granulocyte-Macrophage Colony-Stimulating Factor Regulates Myeloid Inflammation and T Cell Immunity in Pancreatic CancerCancer Cell, 2012
- EMT and Dissemination Precede Pancreatic Tumor FormationCell, 2012
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- The Efficacy of Radiotherapy Relies upon Induction of Type I Interferon–Dependent Innate and Adaptive ImmunityCancer Research, 2011
- CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and HumansScience, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Conditional variable importance for random forestsBMC Bioinformatics, 2008
- Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccinesBlood, 2008